2026 Q3 - tulosraportti
23 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 8 305 | ||
| 2 140 | ||
| 4 709 | ||
| 3 082 | ||
| 17 107 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 16 t sittenSince Stenocare has not announced anything, I assume that they have not signed any agreement. If you, like me, do not have a complete grasp of it, you can advantageously read on. I have geeked out a bit because I did not want to rejoice too early over this news if I have misunderstood something. It is Becanex that has taken over Bedrocan in Canada, as well as the Bedrocan brand itself. The Erkelens family continues to run and manage the production in Canada under Becanex. What they have done is that they have managed to have cuttings transported from the Dutch mother plant to Canada in 2025, and therefore these mentioned plants have the same genetics as the ones Stenocare has imported from the Netherlands. Even though the plants have the same genetics, they must be approved again by the Danish Medicines Agency (Lægemiddelstyrelsen). They must do this because they are now cultivated in Canada. If Stenocare signs an agreement: If no further questions arise from the Danish Medicines Agency, we can expect it to take between 3-6 months for the plants to be approved in Denmark. Fortunately, it is not so expensive to apply for permission in Denmark, and it is also tax-deductible, and therefore it will not crash Stenocare's budget. It costs 56,059 DKK in a one-time fee per plant that Stenocare wants to have approved. https://bedrocan.com/direct-orders-can-now-be-placed-at-bedrocan/ It is 7009 that is the mentioned price https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/gebyrer/
- ·22 t sittenAfter medicinal flower lost its reimbursement in Germany, businesses that primarily focused on that area have started filing for bankruptcy. Until now, I have discovered that Apotheke Lux 99, which built its business around prescription medicinal flower, and Cannameleon, within CBD and hemp, which bet on being able to get medicinal flower as part of their assortment. It is not unthinkable that there will be more filings in the same drawer. TS has stated several times during various webcasts that because Weeco Astrum 10/10 is prescription medicine and has continued to keep 100 % reimbursement, they will end up standing stronger in Germany. https://www.pharmazeutische-zeitung.de/warum-gerade-so-viele-cannabis-unternehmen-scheitern-171461/
- ·3 päivää sittenfun facts: THC in 2,800 year old hair: Scientific study provides earliest evidence of high cannabis content https://www.hanf-magazin.com/en/thc-in-2-800-jahre-alten-haaren-science-studie-liefert-fruehesten-beleg-fuer/
- ·16.11.When do we believe in new loan capital or a share issue???
- ·13.11.The latest news I can find from France regarding how far the decree has reached before HAS can begin pricing and subsidies for cannabis oils etc. The decree is now on the Conseil d'État's desk (France's highest administrative court and the government's primary legal advisor). According to the article below, they maintain the deadline that French pharmacies will have cannabis oils in their assortment for sale in early 2027. https://internationalcbc.com/new-report-details-frances-medical-cannabis-status/For info, Mado Gilanton, president of the patient association APAISER S&C, who leads a coalition of over 14 French patient associations, representing around 100,000 seriously ill patients who will be eligible for prescription medical cannabis when the permanent scheme enters into force
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
23 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 16 t sittenSince Stenocare has not announced anything, I assume that they have not signed any agreement. If you, like me, do not have a complete grasp of it, you can advantageously read on. I have geeked out a bit because I did not want to rejoice too early over this news if I have misunderstood something. It is Becanex that has taken over Bedrocan in Canada, as well as the Bedrocan brand itself. The Erkelens family continues to run and manage the production in Canada under Becanex. What they have done is that they have managed to have cuttings transported from the Dutch mother plant to Canada in 2025, and therefore these mentioned plants have the same genetics as the ones Stenocare has imported from the Netherlands. Even though the plants have the same genetics, they must be approved again by the Danish Medicines Agency (Lægemiddelstyrelsen). They must do this because they are now cultivated in Canada. If Stenocare signs an agreement: If no further questions arise from the Danish Medicines Agency, we can expect it to take between 3-6 months for the plants to be approved in Denmark. Fortunately, it is not so expensive to apply for permission in Denmark, and it is also tax-deductible, and therefore it will not crash Stenocare's budget. It costs 56,059 DKK in a one-time fee per plant that Stenocare wants to have approved. https://bedrocan.com/direct-orders-can-now-be-placed-at-bedrocan/ It is 7009 that is the mentioned price https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/gebyrer/
- ·22 t sittenAfter medicinal flower lost its reimbursement in Germany, businesses that primarily focused on that area have started filing for bankruptcy. Until now, I have discovered that Apotheke Lux 99, which built its business around prescription medicinal flower, and Cannameleon, within CBD and hemp, which bet on being able to get medicinal flower as part of their assortment. It is not unthinkable that there will be more filings in the same drawer. TS has stated several times during various webcasts that because Weeco Astrum 10/10 is prescription medicine and has continued to keep 100 % reimbursement, they will end up standing stronger in Germany. https://www.pharmazeutische-zeitung.de/warum-gerade-so-viele-cannabis-unternehmen-scheitern-171461/
- ·3 päivää sittenfun facts: THC in 2,800 year old hair: Scientific study provides earliest evidence of high cannabis content https://www.hanf-magazin.com/en/thc-in-2-800-jahre-alten-haaren-science-studie-liefert-fruehesten-beleg-fuer/
- ·16.11.When do we believe in new loan capital or a share issue???
- ·13.11.The latest news I can find from France regarding how far the decree has reached before HAS can begin pricing and subsidies for cannabis oils etc. The decree is now on the Conseil d'État's desk (France's highest administrative court and the government's primary legal advisor). According to the article below, they maintain the deadline that French pharmacies will have cannabis oils in their assortment for sale in early 2027. https://internationalcbc.com/new-report-details-frances-medical-cannabis-status/For info, Mado Gilanton, president of the patient association APAISER S&C, who leads a coalition of over 14 French patient associations, representing around 100,000 seriously ill patients who will be eligible for prescription medical cannabis when the permanent scheme enters into force
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 8 305 | ||
| 2 140 | ||
| 4 709 | ||
| 3 082 | ||
| 17 107 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
23 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 22.10.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- 16 t sittenSince Stenocare has not announced anything, I assume that they have not signed any agreement. If you, like me, do not have a complete grasp of it, you can advantageously read on. I have geeked out a bit because I did not want to rejoice too early over this news if I have misunderstood something. It is Becanex that has taken over Bedrocan in Canada, as well as the Bedrocan brand itself. The Erkelens family continues to run and manage the production in Canada under Becanex. What they have done is that they have managed to have cuttings transported from the Dutch mother plant to Canada in 2025, and therefore these mentioned plants have the same genetics as the ones Stenocare has imported from the Netherlands. Even though the plants have the same genetics, they must be approved again by the Danish Medicines Agency (Lægemiddelstyrelsen). They must do this because they are now cultivated in Canada. If Stenocare signs an agreement: If no further questions arise from the Danish Medicines Agency, we can expect it to take between 3-6 months for the plants to be approved in Denmark. Fortunately, it is not so expensive to apply for permission in Denmark, and it is also tax-deductible, and therefore it will not crash Stenocare's budget. It costs 56,059 DKK in a one-time fee per plant that Stenocare wants to have approved. https://bedrocan.com/direct-orders-can-now-be-placed-at-bedrocan/ It is 7009 that is the mentioned price https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/gebyrer/
- ·22 t sittenAfter medicinal flower lost its reimbursement in Germany, businesses that primarily focused on that area have started filing for bankruptcy. Until now, I have discovered that Apotheke Lux 99, which built its business around prescription medicinal flower, and Cannameleon, within CBD and hemp, which bet on being able to get medicinal flower as part of their assortment. It is not unthinkable that there will be more filings in the same drawer. TS has stated several times during various webcasts that because Weeco Astrum 10/10 is prescription medicine and has continued to keep 100 % reimbursement, they will end up standing stronger in Germany. https://www.pharmazeutische-zeitung.de/warum-gerade-so-viele-cannabis-unternehmen-scheitern-171461/
- ·3 päivää sittenfun facts: THC in 2,800 year old hair: Scientific study provides earliest evidence of high cannabis content https://www.hanf-magazin.com/en/thc-in-2-800-jahre-alten-haaren-science-studie-liefert-fruehesten-beleg-fuer/
- ·16.11.When do we believe in new loan capital or a share issue???
- ·13.11.The latest news I can find from France regarding how far the decree has reached before HAS can begin pricing and subsidies for cannabis oils etc. The decree is now on the Conseil d'État's desk (France's highest administrative court and the government's primary legal advisor). According to the article below, they maintain the deadline that French pharmacies will have cannabis oils in their assortment for sale in early 2027. https://internationalcbc.com/new-report-details-frances-medical-cannabis-status/For info, Mado Gilanton, president of the patient association APAISER S&C, who leads a coalition of over 14 French patient associations, representing around 100,000 seriously ill patients who will be eligible for prescription medical cannabis when the permanent scheme enters into force
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 8 305 | ||
| 2 140 | ||
| 4 709 | ||
| 3 082 | ||
| 17 107 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt






